Krystal Biotech, Inc.
KRYS
株式のランク
#2178
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
株価
$317.87
最終同期: 2026-10-16
時価総額
$9.41B
変化（1日）
-3.68%
変化（1年）
67.10%
国
US
取引 Krystal Biotech, Inc. (KRYS)
カテゴリー
Healthcare
Krystal Biotech, Inc.（KRYS）の営業利益率
October 2026 時点の営業利益率 TTM: 44.93%
Krystal Biotech, Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は 44.93% です。2023 年末時点では -216.43% でした。
Krystal Biotech, Inc. の営業利益率の履歴（2016 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 44.93% | 98.72% |
| 2024 | 22.61% | -110.45% |
| 2023 | -216.43% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -1,160.27% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -99.14% |
US
|
|
| -149.01% | -103.32% |
US
|
|
| 25.57% | -99.43% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.36% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。